Share on StockTwits

Questcor Pharmaceuticals (NASDAQ:QCOR) EVP David Jeffrey Medeiros unloaded 2,292 shares of Questcor Pharmaceuticals stock on the open market in a transaction dated Monday, April 21st. The shares were sold at an average price of $77.15, for a total transaction of $176,827.80. Following the sale, the executive vice president now directly owns 120,039 shares in the company, valued at approximately $9,261,009. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

A number of analysts have recently weighed in on QCOR shares. Analysts at Oppenheimer reiterated an “outperform” rating on shares of Questcor Pharmaceuticals in a research note on Monday. They now have a $86.00 price target on the stock, down previously from $99.00. Separately, analysts at Mizuho cut their price target on shares of Questcor Pharmaceuticals from $93.00 to $92.00 in a research note on Tuesday, April 8th. Finally, analysts at Jefferies Group downgraded shares of Questcor Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 8th. They now have a $86.00 price target on the stock, down previously from $89.00. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $84.20.

Questcor Pharmaceuticals (NASDAQ:QCOR) traded up 2.47% during mid-day trading on Wednesday, hitting $80.07. 1,647,748 shares of the company’s stock traded hands. Questcor Pharmaceuticals has a 52-week low of $28.93 and a 52-week high of $85.69. The stock has a 50-day moving average of $69.74 and a 200-day moving average of $63.32. The company has a market cap of $4.706 billion and a price-to-earnings ratio of 16.42.

Questcor Pharmaceuticals (NASDAQ:QCOR) last released its earnings data on Tuesday, February 25th. The company reported $1.67 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.66 by $0.01. The company had revenue of $243.00 million for the quarter, compared to the consensus estimate of $244.15 million. Analysts expect that Questcor Pharmaceuticals will post $7.05 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Tuesday, July 8th. Shareholders of record on Tuesday, July 1st will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 1.50%.

Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.